Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,599 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection.
Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, Pawlotsky JM, Neumann AU, Ferrari C, Missale G, Haagmans BL, Schalm SW, Zeuzem S, Negro F, Verheij-Hart E, Hellstrand K; DITTO-HCV Study Group. Romero AI, et al. Among authors: ferrari c. J Infect Dis. 2006 Oct 1;194(7):895-903. doi: 10.1086/507307. Epub 2006 Aug 29. J Infect Dis. 2006. PMID: 16960776 Clinical Trial.
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection.
Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky JM, Zeuzem S, von Wagner M, Negro F, Schalm SW, Haagmans BL, Ferrari C, Missale G, Neumann AU, Verheij-Hart E, Hellstrand K; DITTO-HCV Study Group. Lagging M, et al. Among authors: ferrari c. Hepatology. 2006 Dec;44(6):1617-25. doi: 10.1002/hep.21407. Hepatology. 2006. PMID: 17133471 Clinical Trial.
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C.
Askarieh G, Alsiö A, Pugnale P, Negro F, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Norkrans G, Westin J, Söderholm J, Hellstrand K, Lagging M; DITTO-HCV and NORDynamIC Study Groups. Askarieh G, et al. Among authors: ferrari c. Hepatology. 2010 May;51(5):1523-30. doi: 10.1002/hep.23509. Hepatology. 2010. PMID: 20186843 Clinical Trial.
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms.
Lagging M, Askarieh G, Negro F, Bibert S, Söderholm J, Westin J, Lindh M, Romero A, Missale G, Ferrari C, Neumann AU, Pawlotsky JM, Haagmans BL, Zeuzem S, Bochud PY, Hellstrand K; DITTO-HCV Study Group. Lagging M, et al. Among authors: ferrari c. PLoS One. 2011 Feb 24;6(2):e17232. doi: 10.1371/journal.pone.0017232. PLoS One. 2011. PMID: 21390311 Free PMC article. Clinical Trial.
Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection.
Söderholm J, Waldenström J, Askarieh G, Pilli M, Bochud PY, Negro F, Pawlotsky JM, Zeuzem S, Ferrari C, Norkrans G, Wejstål R, Westin J, Neumann AU, Haagmans BL, Lindh M, Missale G, Hellstrand K, Lagging M. Söderholm J, et al. Among authors: ferrari c. PLoS One. 2013;8(2):e56991. doi: 10.1371/journal.pone.0056991. Epub 2013 Feb 20. PLoS One. 2013. PMID: 23437290 Free PMC article.
Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
Lukasiewicz E, Hellstrand K, Westin J, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Veldt BJ, Hansen BE, Verhey-Hart E, Lagging M. Lukasiewicz E, et al. Among authors: ferrari c. Hepatology. 2007 Jan;45(1):258-9. doi: 10.1002/hep.21505. Hepatology. 2007. PMID: 17187414 No abstract available.
HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).
Pilli M, Zerbini A, Penna A, Orlandini A, Lukasiewicz E, Pawlotsky JM, Zeuzem S, Schalm SW, von Wagner M, Germanidis G, Lurie Y, Esteban JI, Haagmans BL, Hezode C, Lagging M, Negro F, Homburger Y, Neumann AU, Ferrari C, Missale G; DITTO-HCV Study Group. Pilli M, et al. Among authors: ferrari c. Gastroenterology. 2007 Oct;133(4):1132-43. doi: 10.1053/j.gastro.2007.06.059. Epub 2007 Jul 3. Gastroenterology. 2007. PMID: 17919489 Clinical Trial.
1,599 results